Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
AssigneesApnimed, Inc. (Delaware), Brigham and Women' Hospital
InventorsLawrence G. MILLER, Ronald FARKAS, D. Andrew WELLMAN, Luigi TARANTO-MONTEMURRO, Scott Aaron SANDS
Life of this patent
Estimating the term…
Abstract
In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the administration of these pharmaceutical compositions.
Claims80
A method of treating a subject having a condition associated with pharyngeal airway collapse, the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI);
- (ii) a muscarinic receptor antagonist;
- and (iii) a carbonic anhydrase inhibitor.
A pharmaceutical composition comprising (i) a norepinephrine reuptake inhibitor (NRI);
- (ii) a muscarinic receptor antagonist;
- and (iii) a carbonic anhydrase inhibitor, in a pharmaceutically acceptable carrier.
A norepinephrine reuptake inhibitor (NRI), a muscarinic receptor antagonist, and a carbonic anhydrase inhibitor for use in treating a subject having a condition associated with pharyngeal airway collapse.
A kit comprising a norepinephrine reuptake inhibitor (NRI), a muscarinic receptor antagonist, and a carbonic anhydrase inhibitor.
A method of treating a subject having a condition associated with pharyngeal airway collapse, the method comprising administering to a subject in need thereof an effective amount of (i) Atomoxetine;
- (ii) Oxybutynin;
- and (iii) Acetazolamide.
A pharmaceutical composition comprising (i) Atomoxetine;
- (ii) Oxybutynin;
- and (iii) Acetazolamide, in a pharmaceutically acceptable carrier.
A method for lowering loop gain and increasing muscle responsiveness in a subject having obstructive sleep apnea (OSA), the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI);
- (ii) a muscarinic receptor antagonist;
- and (iii) a carbonic anhydrase inhibitor.
A method for lowering loop gain and increasing muscle responsiveness in a subject having obesity hypoventilation syndrome (OHS), the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI);
- (ii) a muscarinic receptor antagonist;
- and (iii) a carbonic anhydrase inhibitor.
Dependencies are inferred from the claim text.